Taken together, these data suggest that loss of tolersusceptibility locus, Sle1, corresponds to three loci ance to chromatin mediated by Sle1 is essential for independently affecting loss of tolerance to chromatin disease pathogenesis and that the proteins encoded by in the NZM2410 mouse. The congenic interval correthese loci and the pathways on which they impact may sponding to Sle1c contains Cr2, which encodes combe important targets for disease intervention in SLE.
). In humans, CR1 and CR2 are generated from dsDNA autoantibodies and the evolution of a fatal imtwo distinct but closely linked genes on chromosome mune complex-mediated glomerulonephritis. Disease 1. The murine Cr2 gene encodes both the 190 kDa CR1 susceptibility has been linked to genes derived from protein consisting of 21 repeating structures (termed both the NZB and NZW parental strains. Various strateshort consensus repeats or SCRs), a transmembrane gies have been used to identify the specific diseasedomain, and a short cytoplasmic tail, as well as the related genes in these animals. One approach has utialternatively spliced 140 kDa CR2 protein, containing lized the lupus-prone NZM2410 strain, a recombinant the 15 membrane-proximal SCRs of CR1 plus its transinbred strain derived from (NZB ϫ NZW)F 1 mice (Rudofmembrane domain and cytoplasmic tail. CR1 and CR2 sky et al., 1993). NZM2410 mice exhibit a severe lupus are surface glycoproteins that, in the mouse, are located phenotype, including fatal glomerulonephritis. We have almost exclusively on mature B cells and follicular denidentified by linkage analysis three recessive loci strongly dritic cells (FDC). These receptors bind C3 and C4 degraassociated with lupus susceptibility in this strain (Sle1, dation products that have become covalently bound to Sle2, and Sle3 located on chromosomes 1, 4, and 7, antigen or immune complexes in the process of complerespectively) (Morel et al., 1994 developed, which is usually mild and occurs late, was more severe and had a much earlier onset (Prodeus et al., 1998). These data suggest that alterations in expres- (Molina et al., 1994) . After SDS-PAGE and immunoblotsion or function of CR1/CR2 may affect negative selecting with HRP-streptavidin, CR1 and CR2 from B6.Sle1c tion of autoreactive B cells, resulting in the initiation or were found to migrate at a higher molecular weight than exacerbation of SLE. the corresponding proteins from B6 animals ( Figure 2A ). Because of the previous association of CR1/CR2 defiThis difference was due to differential glycosylation of ciency with autoimmune disease and the location of the the proteins, as treatment with PNGaseF reduced the Cr2 gene within the Sle1c disease susceptibility locus, proteins from the two strains to equivalent molecular we analyzed the Sle1c (NZW) allele of Cr2 in B6.Sle1c weights ( Figure 2B ). To ensure that this difference did mice for alterations in structure, function, and expresnot reflect a global alteration in glycosylation of B cell sion. We identified a structural difference in a critical surface receptors in the B6.Sle1c strain, CD19 and CD22 ligand binding domain of Sle1c CR1/CR2, which results were analyzed in a similar fashion and were found to be in significant impairment in receptor function. These resimilar in size in B6 and B6.Sle1c, whether glycosylated sults demonstrate a functionally significant effect of the or deglycosylated ( Figure 2B ). These data demonstrate NZM2410 Cr2 allele and strongly support its role as a that the enhanced glycosylation of CR1 and CR2 in disease susceptibility gene in this interval.
B6.Sle1c is an alteration unique to these two proteins.
A Single-Nucleotide Polymorphism (SNP) in NZW Cr2

Results
Introduces a Novel N-Linked Glycosylation Site in the Ligand Binding Domain of CR1/CR2 The NZW Allele of Cr2, Located within the Sle1c Disease Susceptibility Interval, Generates
Having identified an alteration in the structure of CR1/ CR2, the sequence of Cr2 in B6.Sle1c mice was then Protein Products that Are Structurally Different from Their B6 Counterparts determined in order to identify nucleotide polymorphisms that might confer new N-linked glycosylation The subcongenic strain B6.Sle1c was derived from the parental B6.Sle1 strain by generation of mice with resites. At nucleotide 1342, a base change of C to A was identified, resulting in an amino acid change of histidine combinant intervals that maintained a positive phenotype for loss of tolerance to chromatin (Morel et al., to asparagine. This introduced a new N-linked glycosylation site into SCR1 of CR2 ( Figure 2C ), which corre-2001). B6.Sle1c mice specifically contain the congenic NZM2410 interval that spans the microsatellite marker sponds to SCR7 of CR1. It also resulted in a new BsmI restriction endonuclease site, allowing genomic DNA D1Mit274 to the telomeric end of chromosome 1. We have previously shown that this NZM2410 region was from a panel of autoimmune and nonautoimmune mouse strains to be tested for the presence of this polymorderived from NZW (Morel et al., 1996) . The Sle1c interval is approximately 3 cM in length, and contains several phism. In addition to NZW, only two other strains in this group share this polymorphism: NOD, which develops potential SLE susceptibility genes, including Cr2, Crry, and Cd34 (Figure 1) . autoimmune diabetes (Leiter, 1993), and SWR, which when crossed with NZB results in female progeny that To determine whether the Cr2 gene products were altered in B6.Sle1c mice, CR1 and CR2 were immunodevelop a severe lupus-like disease (Eastcott et al., 1983). Both of these strains share common ancestry precipitated from surface-biotinylated splenic cell suspensions with a mAb to CR1/CR2, 7E9, which binds to through their derivation from "Swiss" mice (Leiter, 1998). Four other autoimmune strains (BXSB, MRL, NZB, and an epitope within the SCRs common to both receptors (Table 1) . Interestingly, CR1/CR2 in SWR and NOD also migrate at higher apparent molecular weights than the B6 proteins in SDS-PAGE, with initial analyses of the glycosylation status of these proteins strongly suggesting that the molecular weights of the core proteins are equivalent (data not shown). No other glycosylation sites introduced by unique polymorphisms in the N2W, SWR and NOD Cr2 genes were identified. These data suggest that the novel glycosylation site introduced by the polymorphism in SCR1 of CR2 is utilized in each strain in which it is present.
A total of 16 nucleotide sequence differences were identified in the NZW Cr2 allele as compared with B6. This represents a mutation rate that is ‫-3ف‬fold higher (Table 1) . The polymorphisms in SCR13/SCR7 and SCR16/SCR10 formed. 8C12 is specific for an epitope within SCR3 and SCR4 of CR1 (Molina et al., 1994) , while 4E3 binds both had the same strain distribution pattern as the SCR7/ SCR1 polymorphism, while the SCR5 polymorphism receptors at a shared epitope within SCR1 and SCR2 of CR2 (SCR7 and SCR8 of CR1). The expression of CR1 was shared with SJL, and the SCR9/SCR3 polymorphism was shared with MRL, NZB, BALB/c, and DBA/2. and CR2 on the cell surface was equivalent in B6 and B6.Sle1c ( Figures 3C and 3D) . These results are also The SNPs in the transmembrane and cytoplasmic domains were unique to NZW. consistent with the similar levels of protein that are immunoprecipitated from each strain (Figure 2A and 2B 
SCR1 polymorphism with NZW, along with the polymor-
Previous studies have suggested that Cr2 deficiency alone on a B6 background does not confer severe autophisms in SCR7 and SCR10 of CR2 (SCR13 and SCR16 of CR1). These three polymorphisms may mark an allele immune disease, but may contribute to specific phenotypes (Chen et al., 2000) . Indeed, our studies suggest for Cr2 that confers an autoimmune phenotype when present on the appropriate genetic background. At this that the expression of the NZW CR1/CR2 allele confers only a modest phenotype (autoreactivity to chromatin). time, however, we cannot rule out a role for the other SCR polymorphisms in the effects on ligand binding, However, we propose that the combination of the NZW CR1/CR2 allele with altered alleles from other disease although we believe it most likely that the CR2 SCR1 polymorphism is responsible for these effects. It is likely susceptibility loci can result in a fully penetrant endstage disease phenotype. We and others have shown that this polymorphism also explains the decrease in CR2 signaling identified in B6.Sle1c B cells, although the that autoimmune diseases result from synergistic interactions between susceptibility alleles that each provide polymorphisms in the transmembrane and cytoplasmic domains of B6.Sle1c CR1/CR2 may contribute to this a small contribution to the disease phenotype ( progress. It is possible that incomplete resolution of the was generated by reverse transcription using random hexamers autoimmune phenotype will result from these studies, (Applied Biosystems, Foster City, California), and PCR products generated from cDNA using the following primer sets:
suggesting that other disease-related genes located within the Sle1c interval are contributing to the pheno-
type. We are currently generating recombinant strains
Cr2-2 -5Ј-GGAGATGGCTGAGGTGACTC-3Ј
to narrow the interval containing Cr2 so that we can 
